References
Guidelines and research cited across this site.
Cited sources
- Burnett AL, Nehra A, Breau RH, et al. Erectile dysfunction: AUA guideline. J Urol. 2018;200(3):633-641. View source
- Mulhall JP, Trost LW, Brannigan RE, et al. Evaluation and management of testosterone deficiency: AUA guideline. J Urol. 2018;200(2):423-432. Validity reviewed and confirmed by the AUA in 2024. View source
- Nehra A, Alterowitz R, Culkin DJ, et al. Peyronie's disease: AUA guideline. J Urol. 2015;194(3):745-753. View source
- Schlegel PN, Clark JY, Coward RM, et al. Vasectomy: AUA guideline, part I. J Urol. 2026. doi:10.1097/JU.0000000000004861. View source
- Shindel AW, Althof SE, Carrier S, et al. Disorders of ejaculation: an AUA/SMSNA guideline. J Urol. 2022. doi:10.1097/JU.0000000000002392. View source
- Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol. 1994;151(1):54-61. View source
- Lincoff AM, Bhasin S, Flevaris P, et al.; TRAVERSE Study Investigators. Cardiovascular safety of testosterone-replacement therapy. N Engl J Med. 2023;389(2):107-117. View source
- U.S. Department of Health and Human Services. FDA requests updates to testosterone therapy labeling. June 2026. View source
- U.S. Food and Drug Administration. FDA issues class-wide labeling changes for testosterone products. February 2025. View source
- European Association of Urology. EAU Guidelines on Sexual and Reproductive Health. Arnhem, The Netherlands: EAU Guidelines Office; 2026 edition. View source
Guideline links point to the publishing organization. Always check for the latest version.